Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 89

1.

The association of reduced folate carrier 80G>A polymorphism to outcome in childhood acute lymphoblastic leukemia interacts with chromosome 21 copy number.

Gregers J, Christensen IJ, Dalhoff K, Lausen B, Schroeder H, Rosthoej S, Carlsen N, Schmiegelow K, Peterson C.

Blood. 2010 Jun 10;115(23):4671-7. doi: 10.1182/blood-2010-01-256958. Epub 2010 Mar 24.

2.

Reduced folate carrier expression in acute lymphoblastic leukemia: a mechanism for ploidy but not lineage differences in methotrexate accumulation.

Belkov VM, Krynetski EY, Schuetz JD, Yanishevski Y, Masson E, Mathew S, Raimondi S, Pui CH, Relling MV, Evans WE.

Blood. 1999 Mar 1;93(5):1643-50.

3.

Reduced folate carrier-1 80G>A polymorphism affects methotrexate treatment outcome in rheumatoid arthritis.

Drozdzik M, Rudas T, Pawlik A, Gornik W, Kurzawski M, Herczynska M.

Pharmacogenomics J. 2007 Dec;7(6):404-7. Epub 2007 Feb 27.

PMID:
17325736
4.

Association of genetic polymorphism in the folate metabolic pathway with methotrexate pharmacokinetics and toxicity in childhood acute lymphoblastic leukaemia and malignant lymphoma.

Faganel Kotnik B, Grabnar I, Bohanec Grabar P, Dolžan V, Jazbec J.

Eur J Clin Pharmacol. 2011 Oct;67(10):993-1006. doi: 10.1007/s00228-011-1046-z. Epub 2011 Apr 21.

PMID:
21509569
5.
6.

Reduced folate carrier mutations are not the mechanism underlying methotrexate resistance in childhood acute lymphoblastic leukemia.

Kaufman Y, Drori S, Cole PD, Kamen BA, Sirota J, Ifergan I, Arush MW, Elhasid R, Sahar D, Kaspers GJ, Jansen G, Matherly LH, Rechavi G, Toren A, Assaraf YG.

Cancer. 2004 Feb 15;100(4):773-82.

7.

Relationship of the reduced folate carrier gene polymorphism G80A to methotrexate plasma concentration, toxicity, and disease outcome in childhood acute lymphoblastic leukemia.

Faganel Kotnik B, Dolzan V, Grabnar I, Jazbec J.

Leuk Lymphoma. 2010 Apr;51(4):724-6. doi: 10.3109/10428191003611402. No abstract available.

PMID:
20141435
8.

Reduced folate carrier gene expression in childhood acute lymphoblastic leukemia: relationship to immunophenotype and ploidy.

Zhang L, Taub JW, Williamson M, Wong SC, Hukku B, Pullen J, Ravindranath Y, Matherly LH.

Clin Cancer Res. 1998 Sep;4(9):2169-77.

9.

[Association of single nucleotide polymorphism of reduced folate carrier gene with susceptibility to acute leukemia].

Zhao W, Yue LJ, Chen XW.

Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2011 Aug;28(4):446-9. doi: 10.3760/cma.j.issn.1003-9406.2011.04.020. Chinese.

PMID:
21811990
10.

Homocysteine, pharmacogenetics, and neurotoxicity in children with leukemia.

Kishi S, Griener J, Cheng C, Das S, Cook EH, Pei D, Hudson M, Rubnitz J, Sandlund JT, Pui CH, Relling MV.

J Clin Oncol. 2003 Aug 15;21(16):3084-91.

PMID:
12915598
11.

Reduced folate carrier and dihydrofolate reductase expression in acute lymphocytic leukemia may predict outcome: a Children's Cancer Group Study.

Levy AS, Sather HN, Steinherz PG, Sowers R, La M, Moscow JA, Gaynon PS, Uckun FM, Bertino JR, Gorlick R; Children's Cancer Group Study.

J Pediatr Hematol Oncol. 2003 Sep;25(9):688-95.

PMID:
12972803
12.

Influence of MTHFR and RFC1 polymorphisms on toxicities during maintenance chemotherapy for childhood acute lymphoblastic leukemia or lymphoma.

Shimasaki N, Mori T, Torii C, Sato R, Shimada H, Tanigawara Y, Kosaki K, Takahashi T.

J Pediatr Hematol Oncol. 2008 May;30(5):347-52. doi: 10.1097/MPH.0b013e318165b25d.

PMID:
18458567
13.

Defective transport is a common mechanism of acquired methotrexate resistance in acute lymphocytic leukemia and is associated with decreased reduced folate carrier expression.

Gorlick R, Goker E, Trippett T, Steinherz P, Elisseyeff Y, Mazumdar M, Flintoff WF, Bertino JR.

Blood. 1997 Feb 1;89(3):1013-8.

14.

Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia.

Evans WE, Relling MV, Rodman JH, Crom WR, Boyett JM, Pui CH.

N Engl J Med. 1998 Feb 19;338(8):499-505.

15.

Genetic and epigenetic alterations of the reduced folate carrier in untreated diffuse large B-cell lymphoma.

Kastrup IB, Worm J, Ralfkiaer E, Hokland P, Guldberg P, Grønbaek K.

Eur J Haematol. 2008 Jan;80(1):61-6. Epub 2007 Nov 19.

PMID:
18028428
16.

Reduced folate carrier polymorphism determines methotrexate uptake by B cells and CD4+ T cells.

Baslund B, Gregers J, Nielsen CH.

Rheumatology (Oxford). 2008 Apr;47(4):451-3. doi: 10.1093/rheumatology/ken073. Epub 2008 Mar 3.

PMID:
18316334
17.

Effects of a microRNA binding site polymorphism in SLC19A1 on methotrexate concentrations in Chinese children with acute lymphoblastic leukemia.

Wang SM, Sun LL, Zeng WX, Wu WS, Zhang GL.

Med Oncol. 2014 Jul;31(7):62. doi: 10.1007/s12032-014-0062-0. Epub 2014 Jun 14.

PMID:
24927955
18.
20.

Transcription regulatory polymorphism -43T>C in the 5'-flanking region of SLC19A1 gene could affect rheumatoid arthritis patient response to methotrexate therapy.

Chatzikyriakidou A, Georgiou I, Voulgari PV, Papadopoulos CG, Tzavaras T, Drosos AA.

Rheumatol Int. 2007 Sep;27(11):1057-61. Epub 2007 Apr 3.

PMID:
17404734

Supplemental Content

Support Center